Condition (MeSH)
Cestode Infections
ClinicalTrials.gov lists 63 trials for Cestode Infections or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
6 of the 63 trials are tagged with Cestode Infections itself; the rest are tagged with a narrower condition beneath it.
When did Cestode Infections trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 5 |
| 2022 | 1 |
| 2021 | 6 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 63 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cestode Infections trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 2/3 | 3 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 18 |
| Observational | 31 |
How many Cestode Infections trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 6 |
| Completed | 40 |
| Terminated | 5 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cestode Infections trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 8 |
| National Institute of Mental Health (NIMH) | 2 |
Which drugs are being tested for Cestode Infections? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Albendazole | 6 |
| Niclosamide | 2 |
| Oxfendazole | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Dexamethasone/Dexamethasone acetate | 3 |
| Albendazole and praziquantel | 2 |
| Efficacy of albendazole for early stage intervention of alveolar echinococcosis | 1 |
| 28 days of albendazole 15 mg/kg/day | 1 |
| Oxfendazole three doses | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cestode Infections trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Prolonged hospitalization | 4 | 1 |
Which publications cover Cestode Infections? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Serum IgE levels in white and metis communities in Saskatchewan. | Annals of allergy | 1976 | No |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.